

Plasma vitamin C concentrations and risk of incident respiratory diseases and mortality in the European Prospective Investigation into Cancer-Norfolk population-based cohort study

Running Head: Vitamin C levels and incident respiratory diseases

Phyo Kyaw Myint, Andrew M Wilson, Allan B Clark, Robert N Luben, Nicholas J Wareham, Kay-Tee Khaw

School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK (PKM); Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK (PKM, AMW, ABC); Clinical Gerontology Unit, Department of Public Health and Primary Care, School of Clinical Medicine, University of Cambridge, Cambridge, UK (PKM, RNL, KTK); MRC Epidemiology Unit, Cambridge, UK (NJW)

Professor Phyo Kyaw **MYINT**; *Professor of Medicine of Old Age*
phyo.myint@abdn.ac.uk

Professor Andrew M **WILSON**; *Professor of Respiratory Medicine*
a.m.wilson@uea.ac.uk

Dr Allan B **CLARK**; *Senior Lecturer in Medical Statistics*
Allan.clark@uea.ac.uk

Mr Robert N **LUBEN**; *Senior Research Associate*
Robert.luben@srl.cam.ac.uk

Professor Nicholas J **WAREHAM**; *Director of MRC Epidemiology Unit*
Nick.wareham@mrc-epid.cam.ac.uk

Professor Kay-Tee **KHAW**; *Professor of Clinical Gerontology*
Kk101@medschl.cam.ac.uk

Corresponding author:

Phyo Kyaw Myint
Room 4:013 Polwarth Building,
School of Medicine, Medical Sciences and Nutrition
University of Aberdeen, Foresterhill,
Aberdeen
AB25 2ZD
Tel: +44 (0) 1224 437957 | Fax: +44 (0) 1224 437911
Mail to: phyo.myint@abdn.ac.uk

Sources of support: The EPIC-Norfolk study was supported by grants from the Medical Research Council and Cancer Research UK.

Abbreviations:

COPD: Chronic Obstructive Pulmonary Disease

CV: Coefficient of variation

ENCORE: East Norfolk Commission Record

EPIC-Norfolk: European Prospective Investigation into Cancer-Norfolk

FEV1: Forced expiratory volume in first second

FFQ: Food frequency questionnaire

FVC: Forced vital capacity

ICD: International classification of disease

TDI: Townsend deprivation index.

1 **Abstract**

2 **Background:** Cancerous and non-cancerous respiratory diseases are common and contribute
3 significantly to global disease burden. We aim to quantify the association between plasma
4 vitamin C concentrations as an indicator of high fruit and vegetable consumption and the risk
5 of incident respiratory diseases and associated mortality in a general population.

6 **Methods:** 19,357 men and women aged 40-79 years without prevalent respiratory diseases at
7 the baseline (1993-1997) and participating in the European Prospective Investigation into
8 Cancer (EPIC)-Norfolk study in the UK were followed through March 2015 for both
9 incidence and mortality from respiratory diseases.

10 **Results:** There were a total of 3914 incident events and 407 deaths due to any respiratory
11 diseases (excluding lung cancers), 367 incident lung cancers and 280 lung cancer deaths
12 during the follow up (total person years >300,000 years). Cox proportional hazards models
13 showed, persons in the top quartiles of baseline plasma vitamin C concentrations had a 43%
14 lower risk of lung cancer (HR 0.57; 95%CI:0.41-0.81) than did those in the bottom quartile,
15 independently of potential confounders. The results are similar for non-cancerous any
16 respiratory disease (HR 0.85;0.77-0.95), chronic respiratory diseases (HR0.81;0.69-0.96), and
17 pneumonia (HR0.70;0.59-0.83). The corresponding values for mortality were 0.54(0.35-
18 0.81), 0.81(0.59-1.12), 0.85(0.44-1.66), and 0.61(0.37-1.01), respectively. Confining
19 analyses to non-smokers showed 42% and 53% risk reduction of non-smoking related lung
20 cancers incidence and death.

21 **Conclusions:** Higher levels of vitamin C concentrations as a marker of high fruit and
22 vegetable consumption reduces the risk of cancerous and non-cancerous respiratory illnesses
23 including non-smoking related cancers incidence and deaths.

24

25 **Keywords**

26 • Fruit and vegetable consumption

27 • Vitamin C

28 • Lung cancer

29 • Chronic respiratory disease

30 • Pneumonia

31 • Incidence

32 • Mortality

33

34 **Introduction**

35

36 Respiratory diseases are major causes of mortality and morbidity worldwide. In the UK
37 alone, respiratory disease costs the NHS and society £6.6 billion: £3 billion in costs to the
38 care system, £1.9 billion in mortality costs and £1.7 billion in illness costs [1]. Irreversible
39 progressive chronic respiratory diseases and pneumonia are common in middle and older age
40 and contribute significantly to this burden. Whilst lung cancer incidence is declining in some
41 countries which imposed smoking ban, there remains risk of lung cancers in general as well
42 as the risk of non-smoking related lung cancer.

43

44 Whilst the intake of high fruit and vegetables depicted by plasma vitamin C concentrations
45 are linked to mortality [2] and chronic cardiovascular conditions including stroke [3-7].
46 Whether such dietary health behaviour is linked to respiratory diseases including pneumonia
47 is less well understood. Plasma vitamin C levels can be regarded as a reasonably reliable
48 measure of not just the intake of fruit and vegetables, but the in vivo biologically available
49 vitamin C for human physiological functions because it cannot be synthesized in the body. It
50 is because the main source of vitamin C is from dietary fruit, vegetables, and plant foods in
51 humans but is easily denatured by food preparation methods (e.g. via cooking in water,
52 roasting, or grilling) [8]. It also has a short half-life (≈ 30 min) in the blood [9,10]. Therefore,
53 random plasma vitamin C level is most likely to reflect an individual's habitual dietary
54 pattern as well as method of food preparation.

55

56 The relationship between plasma vitamin C concentrations and the incidence of chronic
57 obstructive pulmonary disease (COPD), pulmonary fibrosis, pneumonia and respiratory
58 mortality including lung cancer deaths, in particular non-smoking related lung cancers and

59 their associated mortality risks were poor understood. We explored these relationships in the
60 European Prospective Investigation into Cancer (EPIC)–Norfolk. Our secondary objective
61 was to examine whether the relationship, if existed, vary by age, sex, smoking status,
62 physical activity level, and lung function assessed by forced expiratory volume in the first
63 second (FEV1). We then further assessed the relationship between higher level of fruit and
64 vegetable consumption and non-smoking related incidence and mortality for these conditions.

65

66

67 **Subjects and Methods**

68

69 Participants

70 Participants were drawn from the EPIC-Norfolk prospective population study. The detailed
71 recruitment method and study protocol of EPIC-Norfolk were described previously [11].

72 Briefly, all eligible community-dwelling adults (aged 40-79 years at the baseline (1993-
73 1997)) from 35 participating general practices in Norfolk, UK, were invited to participate. A
74 total of 30,445 (~40% response) persons provided written consent to participate in the study
75 (99.6% British Caucasians). The Norwich Local Research Ethics Committee approved the
76 study.

77

78 Measurements

79 At the time of the baseline survey, participants completed a detailed health and lifestyle
80 questionnaire and attended health check clinic where trained nurses performed clinical
81 assessments. The data collection methods for variables included in this study are described
82 details in the online supplement [12-17].

83

84 Assessment of Vitamin C levels

85 After overnight storage in a dark box at 4–7 °C, non-fasting blood samples were centrifuged
86 at 2100×g for 15 min at 4 °C. Plasma vitamin C was measured from blood collected one year
87 later when funding was available using fluorometric assay within 1 week of sampling [18].

88 The mean coefficients of variation (CV) were 33.2 µmol/L at the lower end and 102.3
89 µmol/L at the upper end.

90

91 Outcome ascertainment

92 Incident cases were ascertained by using death certificate data and hospital record linkage
93 based on UK Office of National Statistics using International Classification of Disease (ICD),
94 revisions 9 and 10 and National Health Service hospital information systems through
95 ENCORE ((ENCORE – East Norfolk COmmission REcord). Accuracy of this method has
96 been previously validated [19]. Hospitalisation record was linked up to end of March 2015
97 and death was monitored until end March 2015. Conditions of interest are any respiratory
98 conditions (ICD codes 460-519; J00-J99, chronic respiratory conditions ICD codes 490-496;
99 J40-47, pneumonia, ICD 10 J12-J18, B012, B052, B953, B960, B961, J100, J110, J851, Lung
100 cancers (C33-C34) and asthma (J45-J46). Whilst incident and mortality from asthma was
101 included in all non-cancerous respiratory diseases, it was specifically excluded from
102 outcomes as adult/older age onset asthma may have other mechanistic pathways which are
103 non-dietary.

104

105

106

107 Statistical analysis

108 Statistical analysis was performed using Stata Version 14.1/SE (StatCorp, USA, Texas,
109 USA). All tests are two-sided and, as the study is exploratory, no adjustment for multiple
110 comparisons has been made. Any participants with missing value for any of the variables
111 included in the analyses were excluded in individual analyses. Plasma vitamin C
112 concentration was split into quartiles, with cut-points 41, 54, and 66 $\mu\text{mol/L}$. The percentage
113 of predicted normal were calculated for FVC and FEV1 (FVC% predicted and FEV1%
114 predicted respectively) based on the Steel and Coal formula [20]. The incidence of respiratory
115 conditions and respiratory related mortality are reported descriptive, firstly overall and then
116 stratified by the quartiles of plasma vitamin C concentrations.

117
118 Cox proportional hazards models were constructed to determine the association between
119 plasma vitamin C concentrations and the subsequent risk of all respiratory conditions, chronic
120 respiratory disease, and pneumonia. The risks of mortality for each of the selected outcomes
121 were also assessed. To estimate the independent contribution of vitamin C concentration we
122 controlled for 1) age and sex; 2) age, sex, and respiratory function assessed using FVC and
123 FEV1; 3) age, sex, respiratory function, and lifestyle factors (smoking, alcohol consumption,
124 physical activity and BMI); 4) age, sex, respiratory function, lifestyle factors, occupational
125 social class and Townsend index of deprivation; 5) as in model 3 with additional adjustment
126 for prevalent diabetes, myocardial infarction (MI) and stroke; 6) as in model 4 with
127 additional adjustment for history of diabetes, MI and stroke; and finally model 7 was
128 constructed as in model 6 after excluding participants who were taking vitamin C containing
129 supplements.

130
131 To assess the differences in the relationship between plasma concentration of vitamin C at the
132 baseline and the subsequent incidence of respiratory diseases including mortality specifically
133 in different age groups (younger and older (<65 years and ≥65 years)), sex (men and
134 women), smoking status (current smokers and non/ex-smokers), physical activity levels
135 (inactive and active), and respiratory function (good and poor function; people with good
136 function defined as people in the top quartile of FEV1 values) the stratified analyses were
137 repeated for model 6.

138
139 Analyses were then repeated for main analyses for final two models (models 6 and 7)
140 confining first to non-current smokers and then to never-smokers.

141

143 **Results**

144

145 A total of 25,639 individuals attended their first health check in EPIC-Norfolk during 1993-
146 1997, of these 1,410 were excluded as they had an existing diagnosis of cancer leaving
147 24,229 individuals. Of these, 2205 had self-reported respiratory diseases and/or taking
148 bronchodilators or drugs for asthma or COPD at the baseline; this leaves 22,024 individuals.
149 After exclusion of 2,685 individuals who did not have vitamin C measurements and further 3
150 participants with missing follow-up data we included a total of 19,336 men and women in the
151 current study. The mean follow-up was 16.54 years. The total follow-up period for the
152 incidence was 319,937 person-years and for the mortality outcome was 336,473 person-years.
153 There were a total of 3,914 incident cases and 407 deaths during the respective follow up
154 periods.

155

156 **Table 1** shows the sample characteristics by quartiles of plasma vitamin C concentrations.

157 The quartile values were ≤ 41 $\mu\text{mol/L}$, 42-54 $\mu\text{mol/L}$, $>54-\leq 66.0$ $\mu\text{mol/L}$, and >66.0

158 $\mu\text{mol/L}$ for quartiles 1,2, 3 and 4, respectively. This shows significant trends for all selected

159 variables across the plasma vitamin C categories. People with the higher levels of plasma

160 vitamin C levels were younger, had better baseline lung functions, materially less likely to be

161 deprived, lower proportion of men, less likely to be current smokers and consumed less

162 amount of alcohol, had higher level of education and occupational social class, physically

163 more active, and had lower prevalence of chronic co-morbid conditions. The crude rates for

164 all the selected outcomes suggest a direct relationship between higher baseline plasma

165 vitamin C concentrations and a better outcome (lower event rates).

166

167 **Table 2** shows the hazards ratios and their corresponding 95% confidence intervals for
168 development of incident any respiratory diseases including chronic respiratory diseases (e.g.
169 COPD/pulmonary fibrosis etc.) and pneumonia over the follow up period. Compared to the
170 people in the bottom quartiles, the people in the highest levels of baseline plasma ascorbic
171 concentrations had significant 15%, 19% 30% and 47% relative risk reduction of having any
172 respiratory conditions, chronic respiratory diseases, hospitalised pneumonia, and lung cancer
173 respectively in adjusted model (model 6). The corresponding relative risk reduction for
174 mortality from these conditions were 13%, 37% and 34% and 52%, respectively, although
175 these did not reach to statistical significance (**Table 3**) with the exception of lung cancer,
176 which showed relative risk reduction of 46%. Excluding those participants who took vitamin
177 C containing supplements did not alter the association (model 7, Tables 2 &3).

178

179 **Figure 1** (a-d) show the stratified analyses by age groups (younger and older (<65 years and
180 ≥ 65 years)), sex (men and women), smoking status (current smokers, non/ex-smokers),
181 physical activity (active, inactive), and respiratory function (good function defined as top
182 quartile of FEV1 value, and poor function defined as the lower three quartiles) for all
183 outcomes examined for those in top quartile of vitamin C concentrations compared to the
184 bottom quartile. The benefit of high levels of fruit and vegetable consumption depicted by
185 random plasma vitamin C concentrations was associated with younger age but generally all
186 subgroups showed consistent trends towards benefit with regard to all outcomes examined.
187 People with lower FEV1 also appear to be benefited from higher fruit and vegetable
188 consumption compared to people with better FEV1. With reduced statistical power most of
189 the sub-analyses shown in **Supplementary Table 1** for mortality outcome, whilst most of the
190 estimates did not show any significant benefit with regard to mortality due to these conditions

191 but the point estimates are in consistent with potential benefit across age group, sex, smoking
192 status, physical activity, and the level of FEV1.

193 **Supplementary Table 2** shows the results confining to non-smokers and never-smokers for
194 both incidence and mortality of all these respiratory diseases. With lower numbers whilst the
195 95%CI are wider, the point estimates show similar direction. Of note, the non-smoking
196 related lung cancer incidence and mortality showed stronger benefit 42% and 53% relative
197 risk reduction in non-current smokers in people with top quartiles of vitamin C
198 concentrations compared to the bottom quartile. **Supplementary Figure 1** shows the Kaplan-
199 Meier estimates of survival based on different events. The graphs are top-left for all
200 respiratory events, top right for lung cancer events, bottom-left for chronic respiratory disease
201 event, and bottom right for pneumonia events.

202

203

204 **Discussion**

205

206 Plasma vitamin C concentration is a good biomarker of plant food, namely fruit and
207 vegetables intake. We found for the first time that the higher habitual intake of fruit and
208 vegetables depicted by higher plasma vitamin C concentrations at the baseline predict future
209 incidence of any respiratory diseases (excluding cancer), chronic respiratory diseases and
210 hospitalised pneumonia in a general population. Further we demonstrate significant relative
211 risk reduction in lung cancer incidence as well as lung cancer related mortality by higher
212 level of baseline plasma vitamin C concentrations. The observed effects are even more
213 pronounced for non-current smokers. The benefit observed with each higher quartiles of
214 plasma vitamin C is fairly consistent and the most beneficial relative risk reduction was
215 observed in the top quartile and the cut off point for the highest quartile in this study was >66
216 $\mu\text{mol/L}$. Given that one serving of fruit and vegetables in our cohort equates to 20- μmol or 1-
217 SD increase in plasma vitamin C concentration [2], it can be extrapolated from our results
218 that at the level of 3.5 portions of fruit and vegetable consumption could lead to significant
219 health benefit within a general population.

220

221 It is well recognised that fresh rather than cooked or boiled fruit and vegetables are a richer
222 source of vitamin C. Due to their antioxidant property, higher levels of vitamin C are thought
223 to be associated with reduced inflammatory process/insult. However, there appears to be
224 distinct lack of nutritional interventions in respiratory diseases except vitamin
225 supplementation with only a few short term studies evaluating supplementation with
226 vitamins. The link between vitamin C intake and lung cancer incidence has been previously
227 investigated [21]. We have furthered this knowledge and shown that high consumption of

228 fruit and vegetables also potentially have substantial survival benefit with relative risk
229 reduction of 46%.

230

231 One short term study of Vitamin C and E showed no change in lung function in 24 COPD
232 patients [22]. In a larger 5-year trial of more than 20,000 patients with coronary disease, other
233 occlusive arterial disease, or diabetes, there was no difference in lung function or COPD
234 related outcomes [23]. A Cochrane review of vitamin C treatment for pneumonia identified
235 3 prophylactic studies conducted more than 30 years ago involving 2335 people from which
236 37 developed community-acquired pneumonia. In all of these studies there was a significant
237 reduction in the development of pneumonia however only one study (of 674 marine recruits)
238 was a randomised trial and the evidence was felt to be too weak to advocate prophylactic use
239 of vitamin C to prevent pneumonia in the general population [24].

240

241 Data from the Third National Health and Nutrition Examination Survey, a US population-
242 based cross-sectional study suggest that serum vitamin C concentration is independently
243 related to lung function as assessed by FEV1 [25] whereas serum vitamin C concentration is
244 associated with FVC in patients with airflow obstruction [26]. Other authors have shown the
245 concentration of vitamin C to be inversely related to all-cause mortality in adults with
246 obstructive lung disease [27] and mean intake of vitamin C is significantly lower in patients
247 with COPD than controls [28].

248

249 Reactive oxygen species are produced by inflammatory cells including neutrophils and
250 macrophages or are inhaled as environmental agents or cigarette smoke. Oxidants result in
251 cellular damage and may result in apoptosis or cellular necrosis, induce mucous secretion or
252 alter remodelling of extracellular matrix [29] all of which may contribute to the

253 pathophysiology of obstructive lung diseases. Indeed, vitamin C has recently be shown to
254 prevent smoke-induced emphysema in mice that cannot synthesise vitamin C suggesting that
255 vitamin C reduced the oxidative stress caused by cigarette smoking [30] and therefore are not
256 simply a reflection of diet. Interestingly, in the current study, people in the lowest quartile of
257 vitamin C had the highest proportion of those with smoking history – Vitamin C has been
258 shown to be required to have an adequate immune response to influenza virus infection in
259 mice [31] and micronutrient deficiencies (including vitamin C) are associated with impaired
260 immune response and higher burden of respiratory infections in elderly humans [32].

261

262 There are some limitations which worth discussing. The initial response rate was modest
263 (~40%). Nevertheless, the baseline characteristics of the study population were similar to
264 those of other UK population samples, with the exception of slightly lower prevalence of
265 smokers [11] which may be related to healthy responder bias. Whilst the lower prevalence of
266 smoking may have some impact on vitamin C levels, the internal relationships between
267 vitamin C levels and incidence respiratory diseases are unlikely to be affected by this.

268 Moreover, the truncation of distribution is more likely to attenuate the associations. .

269 Although follow-up is virtually complete, using hospital record and death certificate linkage
270 approach may underestimate events that are not admitted to the hospital e.g. milder forms of
271 pneumonia.

272

273 The use of self-reported respiratory conditions may have missed some prevalent respiratory
274 conditions. Plasma vitamin C and other covariates, were made at baseline. These measures as
275 well as lifestyle behaviours, which may affect vitamin C concentration, may have changed
276 over the follow-up period. Due to missing data in some of the variables included in the
277 models, the number of participants included in the analysis reduced with higher level of

278 adjustments but the findings were consistent and adjustments did not particularly attenuate
279 the results.

280

281 We addressed confounding and reverse causality issues by comprehensive adjustment of
282 possible confounders. We also performed sensitivity analysis for supplements usage. The
283 incident cases were identified after 1998, at least one year after the baseline. Prospective
284 relationship between baseline vitamin C concentrations and incidence and mortality also
285 suggests potential causal link, or at least the marker of the conditions examined in this study.
286 We performed sensitivity analyses by confining analyses to those who were non-current
287 smokers and never-smokers.

288

289 To conclude, we found that high plasma vitamin C concentrations at baseline are significantly
290 associated with the lower incidence of lung cancer, any respiratory illness other than lung
291 cancer, chronic respiratory diseases and pneumonia. Additionally, those in highest
292 consumption of fruit and vegetables (Quartile 4 of plasma vitamin C concentrations) also had
293 46% relative risk reduction from lung cancer mortality (53% in those who were non-current
294 smokers at the baseline) compared to the bottom quartile. Therefore, the plasma vitamin C
295 level may be useful in identification of those at risk of these both cancerous and non-
296 cancerous respiratory diseases at the population level. As vitamin C level in plasma is
297 associated with higher fruit and vegetable consumption, increased consumption of fruit and
298 vegetables may reduce the risk of these respiratory conditions and associated health care cost
299 globally.

300 **Figure Legends**

301 **Figure 1:** Hazard ratios for study outcomes in people in the highest quartile group (Q4)
302 compared to the lowest quartile group (Q1) stratified by important factors for model 6.

303 **Figure 1 (a):** Incident respiratory illness

304 **Figure 1 (b):** Incident lung cancer

305 **Figure 1 (c):** Incident chronic respiratory diseases

306 **Figure 1 (d):** Incident pneumonia

307

308 **Acknowledgements**

309 The authors would like to thank the participants of the EPIC-Norfolk cohort. We thank the
310 nutritionist team and data management team of the EPIC-Norfolk cohort. The EPIC-Norfolk
311 study was supported by grants from the Medical Research Council and Cancer Research UK.
312 Funders and sponsors had no role in design and the data collection, analysis, and
313 interpretation of data and the writing of the article and the decision to submit it for
314 publication.

315

316 **Contributors**

317 PKM: design, write up, primary responsibility for final content

318 AMW: design, write up

319 ABC: data analysis, write up

320 RNL: data linkage, write up

321 NJW: design, provide data, write up

322 KTK: design, provide data, write up

323

324 **Conflict of interest**

325 None for all authors.

326

327 **Supplementary information is available at EJCN's website.**

328

329 **References**

- 330 [1] Gupta R and Limb E. The Burden of Lung Disease: A statistics report from the British
331 Thoracic Society. 2nd edition. 28 June 2006 [accessed 27 Nov 2014]
332
- 333 [2] Khaw KT, Bingham S, Welch A, Luben R, Wareham N, Oakes S, et al. Relation between
334 plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a
335 prospective population study. *European Prospective Investigation into Cancer and Nutrition.*
336 *Lancet.* 2001;357:657-63.
337
- 338 [3] Myint PK, Luben RN, Welch AA, Bingham SA, Wareham NJ, Khaw KT. Plasma vitamin
339 C concentrations predict risk of incident stroke over 10 y in 20 649 participants of the
340 European Prospective Investigation into Cancer Norfolk prospective population study. *Am J*
341 *Clin Nutr.* 2008;87:64-9.
342
- 343 [4] Myint PK, Luben RN, Wareham NJ, Bingham SA, Khaw KT. Combined effect of health
344 behaviours and risk of first ever stroke in 20,040 men and women over 11 years' follow-up in
345 Norfolk cohort of European Prospective Investigation of Cancer (EPIC Norfolk): prospective
346 population study. *BMJ.* 2009;338:b349
347
- 348 [5] Ness AR, Powles JW, Khaw KT. Vitamin C and cardiovascular disease: a systematic
349 review. *J Cardiovasc Risk* 1996;3:513-21.
350
- 351 [6] Yokoyama T, Date C, Kokubo Y, Yoshiike N, Matsumura Y, Tanaka H. Serum vitamin C
352 concentration was inversely associated with subsequent 20-year incidence of stroke in a
353 Japanese rural community. The Shibata Study. *Stroke* 2000;31:2287-94.
354
- 355 [7] Voko Z, Hollander M, Hofman A, Koudstaal PJ, Breteler MM. Dietary antioxidants and
356 the risk of ischemic stroke: the Rotterdam Study. *Neurology* 2003;61:1273-5.
357
- 358 [8] Food Standard Agency. EVM review of vitamin C. Eat well, be well. Helping you make
359 healthier choices. Internet: http://www.food.gov.uk/multimedia/pdfs/evm_c.pdf (accessed 15
360 September 2014).
361
- 362 [9] Hickey S, Roberts H. Ascorbate: the science of vitamin C. Napa, CA: Lulu Press, Inc,
363 2004. (ISBN 1-4116-0724-4.)
364
- 365 [10] Hickey S, Roberts H. Misleading information on the properties of vitamin C. *PLoS Med*
366 2005;2:e307.
367
- 368 [11] Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, et al. EPIC-Norfolk: study
369 design and characteristics of the cohort. *European Prospective Investigation of Cancer. Br J*
370 *Cancer* 1999;80(suppl 1):95-103.
371
- 372 [12] Cox B, Huppert F, Whichelow M. The Health and Lifestyle Survey: seven years on.
373 Aldershot, UK, Dartmouth Publishing Company, 1993.
374
- 375 [13] Wareham NJ, Jakes RW, Rennie KL, Schuit J, Mitchell J, Hennings S, et al. Validity
376 and repeatability of a simple index derived from the short physical activity questionnaire used

- 377 in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *Public*
378 *Health Nutr* 2003;6:407–13.
- 379
- 380 [14] Elias P, Halstead K, Prandy K. CASOC: computer-assisted standard occupational
381 coding. London, UK: HMSO, 1993.
- 382
- 383 [15] Shohaimi S, Luben R, Wareham N, Day N, Bingham S, Welch A, et al. Residential area
384 deprivation predicts smoking habit independently of individual educational level and
385 occupational social class. A cross sectional study in the Norfolk cohort of the European
386 Prospective Investigation into Cancer (EPIC-Norfolk). *J Epidemiol Community Health*
387 2003;57:270–6.
- 388
- 389 [16] Townsend, P., Phillimore, P. and Beattie, A. (1988) Health and Deprivation: Inequality
390 and the North. Routledge, London.
- 391
- 392 [17] Welch AA, Luben R, Khaw KT, Bingham SA. The CAFE computer program for
393 nutritional analysis of the EPIC-Norfolk food frequency questionnaire and identification of
394 extreme nutrient values. *J Hum Nutr Dietet* 2005;18:99–116.
- 395
- 396 [18] Vuilleumier J, Keck E. Fluorometric assay of vitamin C in biological materials using a
centrifugal analyser with fluorescence attachment. *J Micronutr Anal* 1989;5:25–34.
- 397
- 398 [19] Sinha S, Myint PK, Luben RN, Khaw KT. Accuracy of death certification and hospital
record linkage for identification of incident stroke. *BMC Med Res Methodol.* 2008;8:74.
- 399
- 400 [20] Roca J, Burgos F, Sunyer J, Saez M, Chinn S, Antó JM, et al. Reference values for
forced spirometry. Group of the European Community Respiratory Health Survey. *Eur*
401 *Respir J.* 1998;11:1354-62.
- 402
- 403 [21] Luo J, Shen L, Zheng D. Association between vitamin C intake and lung cancer: a dose-
response meta-analysis. *Sci Rep.* 2014;4:6161.
- 404
- 405 [22] Wu TC, Huang YC, Hsu SY, Wang YC, Yeh SL. Vitamin E and vitamin C
supplementation in patients with chronic obstructive pulmonary disease. *Int J Vitam Nutr*
406 *Res.* 2007;77:272-9.
- 407
- 408 [23] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of
409 antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-
410 controlled trial. *Lancet.* 2002;360:23-33.
- 411
- 412 [24] Hemilä H, Louhiala P. Vitamin C for preventing and treating pneumonia. *Cochrane*
413 *Database Syst Rev.* 2013;8:CD005532.
- 414
- 415 [25] McKeever TM, Lewis SA, Smit HA, Burney P, Cassano PA, Britton J. A multivariate
416 analysis of serum nutrient levels and lung function. *Respir Res.* 2008;9:67.
- 417
- 418 [26] Ochs-Balcom HM, Grant BJ, Muti P, Sempos CT, Freudenheim JL, Browne RW, et al.
419 Antioxidants, oxidative stress, and pulmonary function in individuals diagnosed with asthma
420 or COPD. *Eur J Clin Nutr.* 2006;60:991-9.

- 421 [27] Ford ES, Li C, Cunningham TJ, Croft JB. Associations between antioxidants and all-
422 cause mortality among US adults with obstructive lung function. *Br J Nutr*. 2014;112:1662-
423 73.
- 424 [28] Ahmadi A, Haghigat N, Hakimrabet M, Tolide-ie H. Nutritional evaluation in chronic
425 obstructive pulmonary disease patients. *Pak J Biol Sci*. 2012;15:501-5.
- 426 [29] ben Anes A, Fetoui H, Bchir S, ben Nasr H, Chahdoura H, Chabchoub E, et al.
427 Increased oxidative stress and altered levels of nitric oxide and peroxynitrite in Tunisian
428 patients with chronic obstructive pulmonary disease: correlation with disease severity and
429 airflow obstruction. *Biol Trace Elem Res*. 2014 ;161:20-31.
- 430
- 431 [30] Koike K, Ishigami A, Sato Y, Hirai T, Yuan Y, Kobayashi E, et al. Vitamin C prevents
432 cigarette smoke-induced pulmonary emphysema in mice and provides pulmonary restoration.
433 *Am J Respir Cell Mol Biol*. 2014;50:347-57.
- 434
- 435 [31] Li W, Maeda N, Beck MA. Vitamin C deficiency increases the lung pathology of
436 influenza virus-infected gulo-/- mice. *J Nutr*. 2006;136:2611-6.
- 437
- 438 [32] Hamer DH, Sempértegui F, Estrella B, Tucker KL, Rodríguez A, Egas J, et al.
439 Micronutrient deficiencies are associated with impaired immune response and higher burden
440 of respiratory infections in elderly Ecuadorians. *J Nutr*. 2009;139:113-9.

441 **Table 1:** Baseline characteristics of men and women of EPIC-Norfolk 39-79 years old at the baseline by plasma vitamin C quartile categories

Characteristics	Vitamin C quartiles				p-for trend
	Q1 (3-41 umol/l) N = 5068	Q2 (42-54 umol/l) N = 4849	Q3 (54.1-66 umol/l) N = 4868	Q4 (66-242 umol/l) N = 4554	
Vit C in plasma (umol/l)	28.19 (9.69)	48.51 (3.71)	60.26 (3.38)	78.77 (13.01)	<0.001
Age (years)	60.07 (9.40)	58.93 (9.39)	58.28 (9.03)	58.53 (9.16)	<0.001
FVC (% pred)	87.99 (18.64)	91.43 (18.64)	94.57 (18.36)	96.32 (18.99)	<0.001
FEV1 (% pred)	88.90 (17.94)	92.42 (17.19)	94.81 (16.62)	95.78 (17.29)	<0.001
Townsend index	-1.82 (2.33)	-2.14 (2.07)	-2.19 (2.08)	-2.16 (2.08)	<0.001
Male	3294 (65.0%)	2629 (54.2%)	1924 (39.5%)	1190 (26.1%)	<0.001
Current smoker	1048 (20.8%)	464 (9.6%)	389 (8.1%)	344 (7.6%)	<0.001
Alcohol consumption (grams/week)	8.98 (14.56)	9.01 (13.28)	8.41 (12.02)	8.41 (11.75)	0.023
BMI > 30 kg/m ²	934 (18.5%)	814 (16.8%)	617 (12.7%)	403 (8.9%)	<0.001
Educational attainment					<0.001
None	2155 (42.5%)	1761 (36.4%)	1627 (33.4%)	1522 (33.4%)	
O-level	472 (9.3%)	498 (10.3%)	494 (10.2%)	525 (11.5%)	
A-Level	1988 (39.2%)	1974 (40.8%)	2016 (41.4%)	1813 (39.8%)	
Degree or higher	452 (8.9%)	611 (12.6%)	728 (15.0%)	693 (15.2%)	
Occupational social class					<0.001

Professional	270 (5.5%)	312 (6.6%)	365 (7.6%)	361 (8.1%)	
Managerial	1508 (30.6%)	1694 (35.7%)	1856 (38.8%)	1859 (41.6%)	
Skilled non-manual	723 (14.7%)	797 (16.8%)	837 (17.5%)	739 (16.5%)	
Skilled manual	1403 (28.5%)	1155 (24.4%)	993 (20.7%)	881 (19.7%)	
Semi-skilled	790 (16.0%)	636 (13.4%)	585 (12.2%)	527 (11.8%)	
Non-skilled	235 (4.8%)	149 (3.1%)	152 (3.2%)	102 (2.3%)	
Physically inactive	3139 (61.9%)	2859 (59.0%)	2749 (56.5%)	2501 (54.9%)	<0.001
Myocardial infarction (yes)	249 (4.9%)	151 (3.1%)	114 (2.3%)	81 (1.8%)	<0.001
Diabetes (yes)	169 (3.3%)	127 (2.6%)	78 (1.6%)	43 (0.9%)	<0.001
Stroke (yes)	100 (2.0%)	57 (1.2%)	52 (1.1%)	45 (1.0%)	<0.001
Outcomes					
Hospitalisations					
All (ex-lung cancer)	1237 (24.4%)	977 (20.1%)	865 (17.8%)	727 (16.0%)	<0.001
Lung cancer	162 (3.2%)	64 (1.3%)	49 (1.0%)	50 (1.1%)	<0.001
Chronic respiratory illnesses	503 (9.9%)	352 (7.3%)	307 (6.3%)	268 (5.9%)	<0.001

Pneumonia	463 (9.1%)	337 (6.9%)	285 (5.9%)	214 (4.7%)	<0.001
Mortality					
All (ex-lung cancer)	147 (2.9%)	104 (2.1%)	86 (1.8%)	70 (1.5%)	<0.001
Lung cancer	143 (2.8%)	56 (1.2%)	45 (0.9%)	36 (0.8%)	<0.001
Chronic respiratory illnesses	51 (1.0%)	23 (0.5%)	17 (0.3%)	14 (0.3%)	<0.001
Pneumonia	63 (1.2%)	48 (1.0%)	41 (0.8%)	29 (0.6%)	<0.001
Incidence (hospitalisation or mortality)					
All (ex-lung cancer)	1274 (25.1%)	1002 (20.7%)	889 (18.3%)	749 (16.5%)	<0.001
Lung cancer	190 (3.7%)	70 (1.4%)	54 (1.1%)	53 (1.2%)	<0.001
Chronic respiratory illnesses	517 (10.2%)	355 (7.3%)	311 (6.4%)	270 (5.9%)	<0.001
Pneumonia	489 (9.6%)	357 (7.4%)	302 (6.2%)	228 (5.0%)	<0.001

442 Data presented are mean (SD) for continuous and number (%) for categorical data. Q1 represents the lowest and the Q4 represents the highest quartiles
443 groups of plasma vitamin C concentrations.
444

445 **Table 2:** Hazard ratios and corresponding 95% confidence intervals for incident any respiratory illness (except lung cancers), lung cancer, chronic respiratory
 446 illnesses and pneumonia by quartiles of plasma vitamin C concentration

	Model 1 (n=19,336):	Model 2 (n=18,890):	Model 3 (n=18,168):	Model 4 (n=17,744)	Model 5 (n=18,168)	Model 6 (n=17,744):	Model 7 (n=16,569)
Any respiratory Condition ¹ (events =3914)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.81 (0.74,0.88)	0.84 (0.78,0.92)	0.93 (0.85,1.01)	0.94 (0.86,1.03)	0.93 (0.85,1.01)	0.95 (0.87,1.04)	0.95 (0.86,1.04)
Q3	0.73 (0.67,0.79)	0.77 (0.71,0.85)	0.87 (0.79,0.95)	0.88 (0.81,0.97)	0.87 (0.80,0.96)	0.89 (0.81,0.98)	0.89 (0.81,0.98)
Q4	0.67 (0.61,0.73)	0.73 (0.66,0.80)	0.82 (0.74,0.90)	0.84 (0.76,0.93)	0.83 (0.75,0.91)	0.85 (0.77,0.95)	0.86 (0.77,0.95)
Lung cancer ² (events=367)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.40 (0.31,0.53)	0.42 (0.32,0.56)	0.58 (0.44,0.77)	0.59 (0.44,0.79)	0.58 (0.44,0.77)	0.59 (0.44,0.79)	0.61 (0.45,0.82)
Q3	0.34 (0.25,0.46)	0.38 (0.28,0.51)	0.51 (0.37,0.70)	0.53 (0.38,0.74)	0.51 (0.37,0.70)	0.53 (0.38,0.74)	0.55 (0.40,0.77)
Q4	0.38 (0.28,0.52)	0.43 (0.31,0.59)	0.55 (0.40,0.78)	0.58 (0.41,0.81)	0.55 (0.39,0.78)	0.57 (0.41,0.81)	0.53 (0.36,0.79)
Chronic Respiratory illnesses (events =1,453)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.68 (0.60,0.78)	0.75 (0.65,0.86)	0.88 (0.76,1.01)	0.90 (0.78,1.04)	0.88 (0.76,1.01)	0.90 (0.78,1.04)	0.90 (0.77,1.04)
Q3	0.58 (0.51,0.67)	0.67 (0.58,0.78)	0.82 (0.71,0.96)	0.85 (0.73,0.99)	0.83 (0.71,0.96)	0.85 (0.73,0.99)	0.85 (0.73,1.00)
Q4	0.54 (0.46,0.63)	0.64 (0.55,0.75)	0.78 (0.66,0.92)	0.81 (0.69,0.96)	0.78 (0.67,0.92)	0.81 (0.69,0.96)	0.80 (0.67,0.95)
Pneumonia (events =1,376)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.77 (0.67,0.88)	0.81 (0.70,0.93)	0.86 (0.74,0.99)	0.87 (0.75,1.01)	0.86 (0.74,0.99)	0.88 (0.76,1.02)	0.88 (0.75,1.02)
Q3	0.68 (0.59,0.79)	0.71 (0.61,0.82)	0.78 (0.67,0.91)	0.79 (0.68,0.93)	0.79 (0.68,0.92)	0.81 (0.69,0.94)	0.81 (0.69,0.95)
Q4	0.55 (0.47,0.65)	0.60 (0.51,0.71)	0.66 (0.56,0.79)	0.68 (0.57,0.81)	0.68 (0.57,0.81)	0.70 (0.59,0.83)	0.70 (0.58,0.85)

447 ¹includes J45-J46, J00-J99, J40-J47, J12-J18, B012, B052, B953, B960, B961, J100, J110, J851; ²includes C33-C34. Q1 represents the lowest and the Q4
448 represents the highest quartiles groups of plasma vitamin C concentrations.
449 Model 1) age and sex; 2) age, sex, and respiratory function assessed using FVC and FEV1; 3) age, sex, respiratory function, and lifestyle factors (smoking,
450 alcohol consumption, physical activity and BMI); 4) age, sex, respiratory function, lifestyle factors, occupational social class and Townsend index of
451 deprivation; 5) as in model 3 with additional adjustment for prevalent diabetes, MI and stroke; 6) (fully adjusted model) as in model 4 with additional
452 adjustment for history of diabetes, myocardial infarction and stroke; and finally model 7 (sensitivity model) was constructed as in model 6 after excluding
453 participants who were taking vitamin C containing supplements.

454

455 **Table 3:** Hazard ratios and corresponding 95%CI for all respiratory deaths, lung cancer deaths chronic respiratory cause as cause of death and pneumonia
 456 deaths by quartiles of plasma vitamin C concentration

	Model 1 (n=19,336):	Model 2 (n=18,890):	Model 3 (n=18,168):	Model 4 (n=17,744)	Model 5 (n=18,168)	Model 6 (n=17,744):	Model 7 (n=16,569)
Any respiratory Condition ¹ (events =407)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.77 (0.6,0.99)	0.78 (0.60,1.01)	0.89 (0.68,1.17)	0.93 (0.71,1.23)	0.89 (0.68,1.17)	0.93 (0.71,1.23)	0.95 (0.72,1.26)
Q3	0.69 (0.53,0.91)	0.74 (0.56,0.98)	0.89 (0.66,1.18)	0.93 (0.69,1.24)	0.89 (0.67,1.18)	0.93 (0.70,1.25)	0.96 (0.71,1.29)
Q4	0.59 (0.44,0.79)	0.68 (0.50,0.91)	0.79 (0.58,1.08)	0.81 (0.59,1.11)	0.80 (0.58,1.09)	0.81 (0.59,1.12)	0.87 (0.62,1.22)
Lung cancer ² (events=280)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.44 (0.32,0.59)	0.46 (0.34,0.63)	0.63 (0.46,0.88)	0.64 (0.46,0.89)	0.63 (0.46,0.87)	0.64 (0.46,0.89)	0.65 (0.46,0.91)
Q3	0.39 (0.28,0.55)	0.44 (0.31,0.61)	0.58 (0.40,0.83)	0.60 (0.41,0.86)	0.58 (0.41,0.83)	0.60 (0.41,0.86)	0.61 (0.42,0.89)
Q4	0.37 (0.25,0.53)	0.40 (0.28,0.59)	0.52 (0.35,0.78)	0.54 (0.35,0.81)	0.52 (0.35,0.78)	0.54 (0.35,0.81)	0.48 (0.30,0.77)
Chronic Respiratory illnesses (events =105)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.50 (0.30,0.81)	0.56 (0.34,0.93)	0.87 (0.52,1.47)	0.96 (0.56,1.64)	0.87 (0.51,1.46)	0.95 (0.56,1.63)	0.93 (0.54,1.6)
Q3	0.40 (0.23,0.70)	0.47 (0.27,0.84)	0.73 (0.40,1.35)	0.83 (0.45,1.54)	0.74 (0.40,1.35)	0.84 (0.45,1.56)	0.81 (0.43,1.53)
Q4	0.38 (0.20,0.69)	0.55 (0.30,1.02)	0.73 (0.38,1.40)	0.84 (0.43,1.64)	0.74 (0.38,1.41)	0.85 (0.44,1.66)	0.63 (0.29,1.41)
Pneumonia (events =181)							
Q1	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Q2	0.82 (0.56,1.19)	0.79 (0.53,1.16)	0.78 (0.52,1.18)	0.85 (0.56,1.28)	0.78 (0.52,1.18)	0.85 (0.56,1.29)	0.86 (0.56,1.32)
Q3	0.76 (0.51,1.14)	0.79 (0.53,1.18)	0.84 (0.55,1.29)	0.90 (0.59,1.38)	0.85 (0.55,1.29)	0.91 (0.60,1.40)	0.97 (0.63,1.50)

Q4	0.54 (0.35,0.86)	0.59 (0.37,0.94)	0.64 (0.40,1.02)	0.61 (0.37,1.00)	0.64 (0.40,1.04)	0.61 (0.37,1.01)	0.66 (0.39,1.10)
----	------------------	------------------	------------------	------------------	------------------	------------------	------------------

457 ¹includes J45-J46, J00-J99, J40-J47, J12-J18, B012, B052, B953, B960, B961, J100, J110, J851; ²includes C33-C34. Q1 represents the lowest and the Q4
458 represents the highest quartiles groups of plasma vitamin C concentrations.
459 Model 1) age and sex; 2) age, sex, and respiratory function assessed using FVC and FEV1; 3) age, sex, respiratory function, and lifestyle factors (smoking,
460 alcohol consumption, physical activity and BMI); 4) age, sex, respiratory function, lifestyle factors, occupational social class and Townsend index of
461 deprivation; 5) as in model 3 with additional adjustment for prevalent diabetes, MI and stroke; 6) (fully adjusted model) as in model 4 with additional
462 adjustment for history of diabetes, myocardial infarction and stroke; and finally model 7 (sensitivity model) was constructed as in model 6 after excluding
463 participants who were taking vitamin C containing supplements.

464
465
466
467
468

